News of Note—New CRISPR R&D head; Homology raises $83.5M; Cellectar collaboration

AZ's cancer head jumps ship as Homology gets a big series B and Cellectar signs a Swiss biotech deal.

> After jumping ship from a troubled AstraZeneca, its former head of oncology, Tony Ho, M.D., has climbed aboard preclinical gene editing biotech CRISPR Therapeutics. He becomes EVP and head of R&D at the company and will oversee its global research efforts across all therapeutic areas. Release

> Homology Medicines has got off an impressive $83.5 million series B financing round for work on its in vivo gene editing tech in rare genetic diseases. It had help from a host of VCs, including Deerfield Management, Maverick Ventures, Novartis, 5AM Ventures, ARCH Venture Partners, and many more. Statement

> Cancer biotech Cellectar Biosciences has penned a new collaboration with Swiss biopharma Avicenna Oncology. The pair will work together on new phospholipid drug conjugates, combining Cellectar’s phospholipid ether delivery platform with Avicenna’s cytotoxic payloads. Release

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!